Athira Pharma Stock Net Income
| ATHA Stock | USD 0.64 0.02 3.03% |
Athira Pharma fundamentals help investors to digest information that contributes to Athira Pharma's financial success or failures. It also enables traders to predict the movement of Athira Stock. The fundamental analysis module provides a way to measure Athira Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Athira Pharma stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -117.7 M | -111.8 M | |
| Net Loss | -86.1 M | -81.8 M | |
| Net Loss | -117.7 M | -111.8 M | |
| Net Loss | (3.10) | (2.94) | |
| Net Income Per E B T | 0.82 | 0.75 |
Athira | Net Income |
Athira Pharma Company Net Income Analysis
Athira Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Athira Pharma Net Income | (117.67 M) |
Most of Athira Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Athira Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Athira Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Athira Pharma is extremely important. It helps to project a fair market value of Athira Stock properly, considering its historical fundamentals such as Net Income. Since Athira Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Athira Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Athira Pharma's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Athira Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Athira Pharma reported net income of (117.67 Million). This is 134.48% lower than that of the Biotechnology sector and 267.99% lower than that of the Health Care industry. The net income for all United States stocks is 120.61% higher than that of the company.
Athira Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Athira Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Athira Pharma could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics of similar companies.Athira Pharma is currently under evaluation in net income category among its peers.
Athira Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Athira Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Athira Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Athira Pharma's value.| Shares | Two Sigma Advisers, Llc | 2024-06-30 | 360.9 K | Bristlecone Advisors Llc | 2024-09-30 | 337.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 321.4 K | Geode Capital Management, Llc | 2024-06-30 | 307.2 K | Two Sigma Investments Llc | 2024-06-30 | 302.1 K | Bank Of America Corp | 2024-06-30 | 228.7 K | Bridgeway Capital Management, Llc | 2024-06-30 | 151.1 K | Laird Norton Tyee Trust Co | 2024-06-30 | 147.3 K | State Street Corp | 2024-06-30 | 107.8 K | Perceptive Advisors Llc | 2024-09-30 | 5.4 M | Vanguard Group Inc | 2024-09-30 | 1.6 M |
Athira Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (42.06 M) | ||||
| Shares Outstanding | 38.67 M | ||||
| Shares Owned By Insiders | 1.95 % | ||||
| Shares Owned By Institutions | 62.13 % | ||||
| Number Of Shares Shorted | 1.55 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (116.7 M) | ||||
| Net Income | (117.67 M) | ||||
| Cash And Equivalents | 252.4 M | ||||
| Cash Per Share | 6.67 X | ||||
| Total Debt | 1.58 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 26.40 X | ||||
| Book Value Per Share | 3.41 X | ||||
| Cash Flow From Operations | (100.75 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (2.84) X | ||||
| Target Price | 0.55 | ||||
| Number Of Employees | 65 | ||||
| Beta | 2.84 | ||||
| Market Capitalization | 25.49 M | ||||
| Total Asset | 160.25 M | ||||
| Retained Earnings | (309.21 M) | ||||
| Working Capital | 125.89 M | ||||
| Net Asset | 160.25 M |
About Athira Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Athira Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Athira Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Athira Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:Check out Athira Pharma Piotroski F Score and Athira Pharma Altman Z Score analysis. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.